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Abstract
Background: Cryptopleurine, a phenanthroquinolizidine alkaloid, was known to exhibit anticancer activity; however, the
underlying mechanism is poorly understood. Because the nuclear factor-kB (NF-kB) transcription factors control many
physiological processes including inflammation, immunity, and development and progression of cancer, we investigated
the effects of cryptopleurine on tumor necrosis factor alpha (TNF-a)-induced NF-kB activation pathway and on the
expression of NF-kB-regulated gene products associated with many pathophysiological processes.
Methodology and Principal Finding: MDA-MB231, MDA-MB435, MCF-7, HEK293, RAW264.7 and Hep3B cells were used to
examine cryptopleurine’s effect on the NF-kB activation pathway. Major assays were promoter-reporter gene assay,
electrophoretic mobility shift assay (EMSA), in vitro immune complex kinase assay, real-time PCR, Western blot analysis, and
Matrigel invasion assay. Experiments documenting cell proliferation and apoptosis were analyzed by MTT method and flow
cytometry, respectively. The results indicated that cryptopleurine suppressed the NF-kB activation through the inhibition of
IkB kinase (IKK) activation, thereby blocking the phosphorylation and degradation of the inhibitor of NF-kB alpha (IkBa) and
the nuclear translocation and DNA-binding activity of p65. The suppression of NF-kB by cryptopleurine led to the down-
regulation of gene products involved in inflammation, cell survival, proliferation, invasion, and angiogenesis.
Conclusions and Significance: Our results show that cryptopleurine inhibited NF-kB activation pathway, which leads to
inhibition of inflammation, proliferation, and invasion, as well as potentiation of apoptosis. Our findings provide a new
insight into the molecular mechanisms and a potential application of cryptopleurine for inflammatory diseases as well as
certain cancers associated with abnormal NF-kB activation.
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Introduction
The nuclear factor-kB (NF-kB) transcription factors control
many physiological processes including inflammation, immunity,
apoptosis, and tumor invasion [1,2,3]. NF-kB represents a family
of related DNA-binding proteins, which in mammals includes five
members: NF-kB1 (or p50), NF-kB2 (or p52), RelA (or p65), RelB
and c-Rel. In an inactive state, NF-kB is sequestered in the
cytoplasm as a heterotrimer consisting of p50, p65, and IkB
subunits. On activation, inhibitor of NF-kB alpha (IkBa) under-
goes phosphorylation and ubiquitination-dependent degradation
leading to p65 nuclear translocation and binding to a specific
consensus sequence in the DNA, which results in gene transcrip-
tion.
It is reported that NF-kB regulates more of than 150 genes,
including those involved in immunity and inflammation, anti-
apoptosis, cell proliferation, tumorigenesis and the negative
feedback of the NF-kB signal [4]. NF-kB regulates major
inflammatory cytokines, including interleukin 6 (IL-6), interleukin
8 (IL-8), interleukin-1 beta (IL-1b), many of which are potent
activators for NF-kB [5]. Therefore, NF-kB is primarily an
inducer of inflammatory cytokines. Its inhibitors could be useful as
anti-inflammatory agents [6]. In addition to regulating the
expression of genes important for immune and inflammatory
responses, NF-kB also controls the transcription of genes that are
critical in the early and late stages of aggressive cancers, including
cyclooxygenase-2 (COX-2), cyclinD1, apoptosis suppressor pro-
teins such as cellular inhibitor of apoptosis 1 (cIAP1), B-cell
lymphoma 2 (Bcl2), TNF-a receptor-associated factor 2 (TRAF2),
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invasion and angiogenesis such as inter-cellular adhesion molecule
1 (ICAM-1), matrix metalloproteinase (MMP-9) and vascular
endothelial growth factor (VEGF) [7,8]. Therefore, the NF-kB
inhibitors might also be useful as anti-cancer agents.
NF-kB inhibitors including a variety of natural products,
chemicals, metals, metabolites, synthetic compounds, peptides,
and protein (cellular, viral, bacterial, fungal) can be divided into
different groups depended on the target levels of NF-kB signaling:
upstream of IkB kinase (IKK), directly at the IKK complex or IkB
phosphorylation, ubiquitination, proteasomal degradation of IkB,
nuclear translocation of NF-kB, NF-kB-DNA binding, and NF-kB
transactivation [9,10]. To date, a large number of natural
compounds have been reported as NF-kB inhibitors and some
of these have been further investigated for the application in
diseases treatment [11,12].
Cryptopleurine is a phenanthroquinolizidine alkaloid isolated
from the roots of Boehmeria pannosa (Urticaceae). Cryptopleurine
was shown to have potent antiviral activity against herpes virus
and anti-inflammatory [13]. This alkaloid also showed potent
anticancer activity against human gastric cancer cells through
inhibition of hypoxia-inducible factor-1a [14]. Tumor necrosis
factor alpha (TNF-a) is an important proinflammatory factor that
acts as a master switch in establishing an intricate link between
Figure 1. Cryptopleurine inhibits NF-kB activation by different stimuli. (A) Structure of cryptopleurine. (B) MDA-MB231 cells (upper panel)
and Hep3B cells (lower panel) were preincubated with indicated concentrations of cryptopleurine for 12 h and then treated with TNF-a (20 ng/ml) for
15 min. Nuclear extracts were then prepared and assayed for NF-kB activation by EMSA. In lane AP-1, a 100-fold excess of unlabeled AP-1 consensus
oligonucleotide was added to the reaction mixture. In lane kB, a 100-fold excess of unlabeled kB consensus oligonucleotide was added to the
reaction mixture. The arrow indicates the location of the DNA-NF-kB complex. (C) MDA-MB435, and MCF-7 cells were incubated with 30 nM
cryptopleurine for 12 h and then incubated with 20 ng/ml TNF-a for 15 min. Nuclear extracts were then prepared and assayed for NF-kB activation
by EMSA. (D) Hep3B, and RAW264.7 cells were preincubated with 30 nM cryptopleurine for 12 h and then treated with 25 ng/ml PMA or 1 mg/ml LPS
for 90 min. Nuclear extracts were then prepared and assayed for NF-kB activation by EMSA.
doi:10.1371/journal.pone.0040355.g001
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of the tissue architecture necessary for tumor growth and
metastasis. It also induces other cytokines and angiogenic factors
and thus contributes to the increased growth and survival of tumor
cells. A wide variety of evidence has pointed to a critical role of
TNF-a and the NF-kB pathway on cancer cell survival, pro-
liferation, invasion, and angiogenesis [16,17]. The results de-
scribed below showed that cryptopleurine inhibits the TNF-a-
induced IkB kinase (IKK) activation, thereby blocking the
activation of NF-kB through the inhibition of IkBa phosphory-
lation and degradation, and p65 nuclear translocation and DNA-
binding activity. Furthermore, the suppression of NF-kBb y
cryptopleurine led to the down-regulation of gene products
involved in inflammation (IL-6, IL-8, and IL-1b), cell survival
(TRAF2, Bcl2, cIAP1, and FLIP), proliferation (cyclinD1 and
COX-2), invasion (ICAM-1 and MMP-9), and angiogenesis
(VEGF).
Results
Cryptopleurine Inhibits NF-kB Activation by Different
Stimuli
In an effort to unravel the molecular mechanism of crypto-
pleurine (Fig. 1A), we investgated its effects on TNF-a-induced
NF-kB activation pathway. In MDA-MB231 cells and Hep3B
cells, cryptopleurine suppressed TNF-a-induced NF-kB activation
in a dose-dependent manner, and this inhibition was observed at
a concentration even as low as 30 nM (Fig. 1B upper panel and
lower panel). Since AP-1 transcription factor is also regulated by
TNF-a, we examined whether the compound show specificity on
the regulation of NF-kB but not AP-1. Electrophoretic mobility
shift assay (EMSA) using excess NF-kB- or AP-1-consensus
oligonucleotide showed that cryptopleurine is not likely to regulate
TNF-a induced AP-1 activity (Fig. 1B lower panel). Similar
inhibitory effect of cryptopleurine on NF-kB activation by TNF-
a was observed in MDA-MD435 and MCF-7 cells (Fig. 1C). Since
PMA and LPS are potent activators of NF-kB [18], we compared
the effect of cryptopleurine on the activation of NF-kB induced by
TNF-a, PMA, and LPS. EMSA showed that cryptopleurine
suppressed the NF-kB activation induced by all these agents
(Fig. 1D), suggesting that cryptopleurine may target one or more
common step to the stimuli in the NF-kB activation pathway.
Cryptopleurine Inhibits TNF-a-Induced IkBa
Phosphorylation and Degradation
To determine how cryptopleurine inhibits TNF-a-induced NF-
kB activation, we exposed the MDA-MB231 cells to cryptopleur-
ine for 12 h and then treated them with TNF-a for different
periods. We then prepared nuclear extracts and cytoplasmic
extracts and analyzed them for NF-kB activation by EMSA and
for phosphorylation and degradation of IkBa by Western blot.
The results showed that TNF-a induced NF-kB activation in
a time-dependent manner and that the earliest activation occurred
within 5 min after TNF-a addition (Fig. 2A, left four lanes).
However, pretreatment of 30 nM of cryptopleurine blocked TNF-
a-induced NF-kB activation (Fig. 2A, right four lanes). TNF-
a induced phosphorylation and degradation of IkBa were also
occurred as quickly as 5 min (Fig. 2B, left five lanes). However,
cryptopleurine potently inhibited the TNF-a-induced phosphory-
lation and degradation of IkBa (Fig. 2B, right five lanes), and this
inhibitory effect was also observed in a dose-dependent manner
(Fig. 2C). Since a rapid degradation of phosphorylated IkBa
occurred in 5 min, we used a proteasome inhibitor ALLN to block
degradation of IkBa. Western blot analysis showed that TNF-
Figure 2. Effect of cryptopleurine on the TNF-a-induced
phosphorylation and degradation of IkBa. (A) MDA-MB231 cells
were incubated with 30 nM cryptopleurine for 12 h and then incubated
with 20 ng/ml TNF-a for the indicated times. Nuclear extracts were then
prepared and assayed for NF-kB activation by EMSA. (B) MDA-MB231
cells were incubated with 30 nM cryptopleurine for 12 h and then
incubated with 20 ng/ml TNF-a for the indicated times. Cytoplasmic
extracts were analyzed by Western blot using indicated antibodies for
p-IkBa,I kBa, and tubulin. (C) MDA-MB231 cells were preincubated with
indicated concentrations of cryptopleurine for 12 h and then treated
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cryptopleurine suppressed both events (Fig. 2D). All of the results
consistently support the idea that cryptopleurine inhibits TNF-a-
induced activation of NF-kB through inhibition of phosphoryla-
tion and degradation of IkBa.
Cryptopleurine Inhibits TNF-a-Induced Activation of IkBa
Kinase, p65 Phosphorylation, and p65 Nuclear
Translocation
Since IKK complex acts as a convergence point for a variety of
upstream signalings and plays a critical role in phosphorylation
and degradation of IkBa proteins [19], we examined whether
cryptopleurine inhibits TNF-a-induced activation of IKK with in
vitro kinase assay. TNF-a induced IKK activation in a time-
dependent manner (Fig. 3A, left five lanes) and cryptopleurine
(30 nM) inhibited this activation (Fig. 3A, right five lanes). Neither
TNF-a nor cryptopleurine had any effect on the expression of
IKK proteins. To evaluate whether cryptopleurine directly
inhibited IKK activity, we immunoprecipitated IKK complex
from 293 cells transfected with IKKa or IKKb after TNF-
a stimulation, and then in vitro kinase assays were conducted in the
presence of various concentrations of cryptopleurine. Results from
the immune complex kinase assay showed that cryptopleurine does
not directly affect the IKK activity (Fig. 3B) but rather modulates
the activation of IKK induced by TNF-a. Since TNF-a also
induces the phosphorylation of p65, which is required for its
transcriptional activity [20], we examined whether cryptopleurine
affects TNF-a-induced phosphorylation of p65 at Ser536. Either
phosphorylated form of p65 or p65 were not detectable in the
nuclear fraction in the presence of cryptopleurine, while TNF-
a alone did induce the phosphorylation and translocation of p65
(Fig. 3C, top and middle panel). Similar results were obtained with
cytoplasmic p65 phosphorylation (Fig. 3D, top and middle panel).
TNF-a induced phosphorylation of p65 time-dependently, how-
ever, cryptopleurine blocked TNF-a induced phosphorylation of
the cytoplasmic of p65 while the p65 level was not significantly
changed (Fig. 3D, top and middle panel). These results indicated
that the inhibition of IKK activation by cryptopleurine would be
associated with the blocking of TNF-a-induced phosphorylation
and nuclear translocation of p65.
Cryptopleurine Inhibits TNF-a-Induced NF-kB-Dependent
Reporter Gene Expression
Next, we investigated whether cryptopleurine modulates NF-
kB-dependent reporter gene expression. After cells were transient-
ly transfected with the NF-kB-regulated luciferase reporter vector,
the cells were further incubated with TNF-a in the presence of
various concentration of cryptopleurine. We found that TNF-a-
induced NF-kB reporter activity was substantially suppressed by
cryptopleurine in a dose-dependent manner (Fig. 4A). Since TNF-
a-induced NF-kB activation pathway, which is mediated through
the sequential interaction of TNFR and TRADD, TRAF2, NIK,
and IKK, results in the phosphorylation and degradation of IkBa
to realease NF-kB [21], we further examine the effects of
cryptopleurine on the TNF-a-induced NF-kB activation pathway
in the MDA-MB231 cells transfected with the NF-kB-regulated
luciferase reporter gene and plasmids expressing TNFR1, TRAF2,
RIP, NIK, IKK, or p65. The cells were then treated with
cryptopleurine and monitored for NF-kB-dependent reporter gene
expression. We found that cryptopleurine suppressed the NF-kB
activation induced by all plasmids but p65 (Fig. 4B). This result
suggest that NF-kB-dependent transcription induced by over-
expression of RelA/p65 was not likely affected by cryptopleurine
significantly, indicating that cryptopleurine could not influence the
transactivation activity of RelA/p65 subunit.
Cryptopleurine Inhibits the Expression of TNF-a-Induced
NF-kB-Dependent Inflammatory Cytokines,
Antiapoptotic, and Proliferation Genes
Next, we investigated the effect of cryptopleurine on TNF-a-
induced expression of IL-6, IL-8, and IL-1b in MDA-MB231 cell.
After MDA-MB231 cells were stimulated with 20 ng/ml TNF-
a for 12 h in the presence or absence of various concentrations of
cryptopleurine, the expression of IL-6, IL-8, and IL-1b was
measured by quantitative real-time PCR. Cryptopleurine signif-
icantly suppressed the TNF-a-induced expression of IL-6, IL-8,
and IL-1b in a dose-dependent manner (Fig. 5A). Because NF-kB
regulates the expression of the antiapoptotic proteins such as,
TRAF2 [22], Bcl2 [23], cIAP1 [24], FLIP [25], we examined
whether cryptopleurine can modulate the expression of these
antiapoptotic genes products induced by TNF-a. MDA-MB231
cells were preincubated with cryptopleurine for 12 h and sub-
sequently stimulated with TNF-a for different periods, and then
the TRAF2, Bcl2, cIAP1, and FLIP expression were analyzed by
Western blot. TNF-a significantly induced the expression of
antiapoptotic proteins in a time-dependent manner, whereas
cryptopleurine markedly suppressed TNF-a-induced expression of
all these proteins (Fig. 5B, top five panels). We also analyzed the
effect of cryptopleurine on the TNF-a-induced expression of
cyclinD1 and COX-2, both of which are associated with tumor
cells proliferation [26,27]. We observed that TNF-a induced the
expression of cyclinD1 and COX-2 and that cryptopleurine
significantly suppressed their expression (Fig. 5B, bottom three
panels). Because cryptopleurine suppressed gene expression in-
volved in proliferation, we examined whether cryptopleurine alone
can modulate the proliferation of various tumor cell types.
Cryptopleurine by itself marginally suppressed the proliferation
of human breast cancer cells (MDA-MB231 and MDA-MB435),
and human hepatic carcinoma cells (Hep3B), and mouse
macrophage cells (RAW264.7) at concentration of 30 nM for
three days treatment (Fig. 5C).
Cryptopleurine Potentiates TNF-a-Induced Apoptosis
Because TNF-a-induced expression of antiapoptotic genes was
downregulated by cryptopleurine, so we examined whether
cryptopleurine enhances apoptosis induced by TNF-a. Crypto-
pleurine potentiated TNF-a-induced apoptosis, as assessed by
Annexin V/PI double staining. As shown in Fig. 6A, combined
treatment resulted in a significant increased the Annexin V-
positive cell population (44.74%), whereas no treatment (4.14%),
treatment with TNF-a alone (11.74%) or cryptopleurine alone
(24.16%) has a little influence on the cell apoptosis. Since caspases
are a group of cysteine proteases critical for apoptosis of eukaryotic
cells [28], we investigated whether cryptopleurine affects TNF-a-
induced activation of caspase-8 and caspase-3. TNF-a alone
negatively and cryptopleurine alone significantly affected the
activation of caspase-8 or caspase-3, whereas cotreatment with
TNF-a and cryptopleurine potentiated their activation, as in-
with TNF-a (20 ng/ml) for 15 min. Cytoplasmic extracts were analyzed
by Western blot using indicated antibodies for p-IkBa,I kBa, and
tubulin. (D) MDA-MB231 cells were preincubated with 30 nM crypto-
pleurine for 12 h, incubated with 50 mg/ml ALLN for 30 min, and then
treated with 20 ng/ml TNF-a for 15 min. Cytoplasmic extracts were
analyzed by Western blot using indicated antibodies for p-IkBa,I kBa,
and tubulin.
doi:10.1371/journal.pone.0040355.g002
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panels). We also used the PARP cleavage assay to detect TNF-a-
induced apoptosis. Again, cryptopleurine potentiated the effect of
TNF-a-induced PARP cleavage, although cryptopleurine alone
also induced PARP cleavage (Fig. 6B, bottom second panel).
These results showed that cryptopleurine enhances the apoptotic
effects of TNF-a.
Cryptopleurine Inhibits TNF-a-Induced Invasion Activity
The expression of ICAM-1, MMP-9 and VEGF, which are
involved in tumor cells invasion and metastasis, is known to be
regulated by NF-kB [29,30,31]. We therefore examined whether
cryptopleurine can suppress the expression of these proteins. TNF-
a treatment induced the expression of ICAM-1, MMP-9 and
VEGF in time-dependent manner, whereas cryptopleurine in-
hibited their expression (Fig. 7A). Reduced expression of ICAM-1,
MMP-9 and VEGF might be responsible for diminished invasion
of tumor cells in cryptopleurine treatment. Therefore, whether
cryptopleurine modulates invasion activity was examined in vitro
with a Matrigel invasion assay. MDA-MB231 cells were seeded in
the top chamber of a Matrigel invasion chamber and were
incubated with various concentrations of cryptopleurine for 24 h.
The result could account for the anti-invasive activity of
cryptopleurine (Fig. 7B).
Figure 3. Effect of cryptopleurine on the TNF-a-induced activation of IkBa kinase, p65 phosphorylation, and p65 nuclear
translocation. (A) HEK293 cells transfected with IKKa or IKKb stimulated with TNF-a for the indicated times in the presence or absence of 30 nM
cryptopleurine. Whole-cell extracts were immunoprecipitated with antibody for IKKa or IKKb, and In vitro kinase assays were performed with GST-IkBa
and [c-
32p]ATP. To show the equal amount of immunocomplex in each reaction, the bottom gels represent IKKa or IKKb detected with Western blot.
(B) HEK293 cells transfected with IKKa or IKKb stimulated with TNF-a for 15 min, and whole-cell extracts were immunoprecipitated with antibody for
IKKa. Indicated concentrations of cryptopleurine was added to the immunoprecipitated IKK complex, incubated for 30 min, and analyzed by an
immune complex kinase assay. MDA-MB231 cells were incubated with 30 nM cryptopleurine for 12 h and then incubated with 20 ng/ml TNF-a for
the indicated times. Nuclear extracts (C) and cytoplasmic extracts (D) were analyzed by Western blot using indicated antibodies for Ser536
phosphorylation in p65, p65, tubulin, and Topo-I.
doi:10.1371/journal.pone.0040355.g003
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The present study reports for the first time that cryptopleurine
inhibits NF-kB. Plant of the Boehmeria pannosa is a rich source of
phenanthroquinolizidine alkaloid. Extracts containing phenan-
throquinolizidine alkaloid, cryptopleurine have been used in
traditional medicine such as anti-viral, anti-fungal, anti-bacterial,
anti-amoebic, and anti-tumor activities [14,32]. Despite of its
various pharmacological activities, its molecular mechanism has
not been sufficiently explained. In this study, we identified
cryptopleurine as a potent inhibitor of stimuli-induced NF-kB
activation and investigated further how this compound suppressed
NF-kB activation.
Our results show that cryptopleurine significantly blocked the
NF-kB activation induced by various stimuli including TNF-a,
PMA, and LPS, suggesting that cryptopleurine interferes with one
or more common steps during NF-kB activation rather than with
one single event. Treatment of cells with cryptopleurine potently
inhibits the IkB phosphorylation and degradation induced by
TNF-a. The IkBa phosphorylation at ser-32 and ser-36 by IKK
complex and subsequently degradation by the ubiquitin/protea-
some pathway is an essential step for NF-kB activation, it is
important to determine whether cryptopleurine directly inhibits
IKK complex activation or the activity of upstream kinase activity.
Our results show that cryptopleurine did not directly inhibit the
activity of IKK but blocked the activation of this kinase. It is well-
known that RelA/p65 is a critical transactivation subunit of NF-
kB [33,34]. The transactivation activity of RelA/p65 subunit is
regulated by posttranslational modifications such as phosphoryla-
tion and acetylation [35]. It was demonstrated that the phosphor-
ylation status of RelA/p65 determines whether it associates with
CREB-binding protein/p300, which is a critical regulator of NF-
kB [36]. Evidence have been presented that IKK is also critical for
the phosphorylation of p65 induced by cytokines such as TNF-
a [5]. These observations led us to further observe if cryptopleur-
ine affect p65 phosphorylation induced by TNF-a. As expected,
our results show that cryptopleurine significantly inhibits TNF-a-
induced RelA/p65 phosphorylation and nuclear translocation.
However, NF-kB activity via overexpression of p65 was not likely
to be inhibited by cryptopleurine as shown with celastrol, which
inhibited IKK activity via C179 modification in the activation
loop of IKK [37]. This further indicated that cryptopleurine do
not affect transcriptional activity of p65.
Increasing evidences suggested NF-kB pathway plays a crucial
role in a link between inflammation and cancer, and demonstrated
an essential role for NF-kB in various cancers and inflammatory
diseases [7,38]. Studies have shown that anti-apoptotic activity of
NF-kB involves the inhibition of TNF-a-induced apoptosis
through induction of a variety of anti-apoptotic [39,40]. Our
results show that cryptopleurine inhibits the TNF-a-induced
expression of antiapoptotic proteins such as TRAF2, Bcl2, cIAP1,
and FLIP, all of which are known to be regulated by NF-kB.
Annexin V staining also showed that TNF-a-induced apoptosis
was enhanced by cryptopleurine. In addition, cryptopleurine
affects TNF-a-induced activation of caspase-8, caspase-3, and
PARP cleavage, although cryptopleurine alone resulted in
minimal effect to their activation. Particulary, cryptopleurine
had a great effect on TNF-a-induced poly(ADP-ribose) poly-
merase cleavage, indicating that the apoptotic effects of TNF-a are
enhanced by cryptopleurine. Positive effect of cryptopleurine alone
on the activation of caspases-8, -3, and PARP cleavage is likely
closely associated with the effect of cryptopleurine on the
antiproliferation and apoptotsis. It is therefore possible that the
activity of cryptopleurine potentiates TNF-a-induced caspases
activity and cancer cell death, at least in part, via its NF-kB
inhibition. NF-kB also controls the genes expression which
important for cell cycle and proliferation [7]. CyclinD1 exercises
powerful control over the mechanisms that regulate the mitotic cell
cycle. COX-2 is a major mediator of cellular proliferation and
survival. The inhibition of the expression of these two genes by
cryptopleurine is likely to be associated with inhibition of the
proliferation of tumor cells as well. MMP-9 and ICAM-1 have
been shown to be expressed in response to NF-kB activation, and
are known to be major mediators of tumor cell invasion [41].
Consequently, regulation of these proteins by cryptopleurine was
accompanied with suppression of tumor cell invasion as demon-
strated in invasion assay. Furthermore, our results indicate that the
expression of VEGF, one of the major mediators of angiogenesis,
is suppressed by cryptopleurine. Taken together with previous
report accounted potent inhibition of hypoxia-inducible factor-1
accumulation in AGS human gastric cancer cells [14], it is highly
Figure 4. Effect of cryptopleurine on the TNF-a-induced NF-kB-
dependent reporter gene expression. (A) MDA-MB231 cells were
transiently transfected with a NF-kB reporter construct pNF-kB-Luc for
24 h. After transfection, cells were incubated with indicated concentra-
tions of cryptopleurine for 12 h and then treated with 20 ng/ml TNF-
a for an additional 12 h. The lysates of MDA-MB231 cells were subject
to the measurement of dual luciferase activity. Data represented as
mean 6 standard deviation of three independent experiments.
**p,0.01, ***p,0.001, significantly different when compared with
TNF-a-stimulated normal cells. (B) MDA-MB231 cells were transiently
transfected with a NF-kB reporter construct pNF-kB-Luc alone or with
plasmids expressing the indicated proteins. After transfection, cells
were incubated with 30 nM cryptopleurine for 12 h and then incubated
with the relevant plasmid for an additional 12 h. TNF-a-treated cells
were incubated with 30 nM cryptopleurine for 12 h and then treated
with 20 ng/ml TNF-a for an additional 12 h. The lysates of MDA-MB231
cells were subject to the measurement of dual luciferase activity. Data
represented as mean 6 standard deviation of three independent
experiments. ***p,0.001, significant with respect to control.
doi:10.1371/journal.pone.0040355.g004
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proliferation, and metastasis.
In summary, our results suggest that cryptopleurine exhibits
antiproliferative, proapoptotic, anti-invasive, antiangiogenic, and
anti-inflammatory effects through the suppression of NF-kB and
NF-kB-regulated gene products. Our results imply that crypto-
pleurine could be an interesting lead compound for the
modulation of inflammatory diseases as well as certain cancers
in which inhibition of NF-kB-activity may be desirable.
Materials and Methods
Cell Culture and Reagents
MDA-MB231, MDA-MB435, HEK293, RAW264.7, and
Hep3B cells were grown in DMEM with penicillin (100 units/
ml)-streptomycin (100 units/ml) (Invitrogen, Carlsbad, CA, USA)
and 10% heat-inactivated fetal bovine serum (Hyclone, Logan,
UT, USA). MCF-7 cells were maintained in RPMI medium
supplemented as above. All cells were purchased from American
Figure 5. Effect of cryptopleurine on the TNF-a-induced NF-kB-dependent inflammatory cytokines, antiapoptotic, and proliferation
genes expression. (A) MDA-MB231 cells were preincubated with indicated concentrations of cryptopleurine for 12 h and then treated with TNF-
a (20 ng/ml) for an additional 12 h. RNA was isolated from cells, reverse-transcribed, and analyzed by real-time PCR for IL-6, IL-8, and IL-1b. Data
represented as mean 6 standard deviation of three independent experiments. *p,0.05, ***p,0.001, significantly different when compared with TNF-
a-stimulated normal cells. (B) MDA-MB231 cells were incubated with 30 nM cryptopleurine for 12 h and then incubated with 20 ng/ml TNF-a for the
indicated times. Whole cell extracts were analyzed by Western blot using indicated antibodies for TRAF2, Bcl2, cIAP1, FLIP, COX-2, cyclinD1, and
tubulin. (C) MDA-MB231, MDA-MB435, RAW264.7, and Hep3B cells were plated in triplicate, treated with 0, 10 or 30 nM cryptopleurine, and subjected
to MTT assay on days 1, 2, 3 to analyze cell proliferation. Absorbance was measured at 570 nm.
doi:10.1371/journal.pone.0040355.g005
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a was obtained from R&D Systems (Minneapolis, MN, USA),
phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharide
(LPS) from Sigma Chemical Co. N-acetyl-leucyl-leucyl-norleucinal
(ALLN) was purchased from Calbiochem (SanDiego, CA, USA).
Cryptopleurine was isolated from Boehmeria pannosa as described
previously [14] and its structures is shown in Fig. 1A. The purity of
cryptopleurine was over 98% in HPLC analysis.
Plasmids, Transfections, and Luciferase Reporter Assay
A pNF-kB-Luc plasmid for NF-kB luciferase reporter assay was
obtained from Strategene (LaJolla, CA, USA). Expression vectors
were obtained as followed: Flag-IKKa, Flag-IKKb, and Flag-p65
(M. Karin, University of California San Diego), Myc-NIK and
Flag-TNFR (M. Jung, Georgetown University), HA-TRAF2 and
HA-RIP were developed in our laboratory. Transfections were
performed as described previously [42]. NF-kB-dependent lucif-
Figure 6. Effect of cryptopleurin on the TNF-a-induced
apoptosis. (A) MDA-MB231 cells were pretreated with 30 nM
cryptopleurine for 12 h and then incubated with 20 ng/ml TNF-a for
24 h, and subsequently stained with Annexin V-FITC and propidium
iodide, followed by analysis using a flow cytometer. Representative
plots of one set of triplicate experiments. Early apoptotic cell (Annexin-
V
+ and PI) were displayed in the lower right quadrant and late apoptotic
cells (Annexin-V
+ and PI
+) were shown in the upper right quadrant. (B)
MDA-MB231 cells were pretreated with 30 nM cryptopleurine for 12 h
and then incubated with 20 ng/ml TNF-a for 24 h. Whole cell extracts
were analyzed by Western blot using indicated antibodies for cleaved
capase-8, cleaved capase-3, cleaved PARP, and tubulin.
doi:10.1371/journal.pone.0040355.g006
Figure 7. Effect of cryptopleurine on the TNF-a-induced
invasion activity. (A) MDA-MB231 cells were incubated with 30 nM
cryptopleurine for 12 h and then incubated with 20 ng/ml TNF-a for
the indicated times. Whole cell extracts were analyzed by Western blot
using indicated antibodies for ICAM-1, MMP-9, VEGF, and tubulin. (B)
MDA-MB231 cells invaded through the pores in the Matrigel-coated
filters were fixed, stained and counted in five random field visualized by
microscopy (1006). Data represented as mean 6 standard deviation of
three independent experiments. ***p,0.001, significant with respect to
control.
doi:10.1371/journal.pone.0040355.g007
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Apoptosis Assays
Annexin V-staining was performed using Annexin V-FITC
apoptosis detection kit (BD Biosciences, CA, USA) following the
instructions of the manufacturer. Briefly, after incubation, cells
were harvested, washed with PBS (pH 7.4), centrifuged, and
stained with Annexin V-FITC and 2 mg/ml propidium iodide in
binding buffer (10 mM Hepes, pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2) for 15 min at 37uC in the dark. The samples were analyzed
by flow cytometry using a FACScan flow cytometer. The
CellQuest software was used to analyze the data (Becton-
Dickinson).
Preparation of Nuclear Extracts and Electrophoretic
Mobility Shift Assay (EMSA)
Electrophoretic mobility shift assay was performed as described
previously [37]. In brief, prior to stimulation, cells were
preincubated with the indicated concentrations of cryptopleurine
at 37uC for 12 h. In following, cells were stimulated, harvested by
centrifugation, washed twice with cold phosphate-buffered saline,
and then nuclear extracts were prepared using NE-PER reagent
(Pierce, Rockford, IL, USA), according to the manufacturer’s
instructions. A double-stranded oligonucleotide for NF-kB (Pro-
mega, Madison, WI, USA) was end-labeled with [c-
32P] ATP and
purified with a G-25 spin column (Boehringer Mannheim,
Mannheim, Germany). Nuclear extracts were incubated for
20 min at room temperature with a gel shift binding buffer [5%
glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM
NaCl, 10 mM Tris-HCl, pH 7.5, 50 mg/ml poly(dI-dC) poly(dI-
dC)] and
32P-labeled oligonucleotide. The DNA-protein complex
formed was separated on 4% native polyacrylamide gel, and the
gel was transferred to Whatman 3 MM paper, dried, and exposed
to X-ray film. The specificity of binding was examined by
competition with an excess of unlabelled oligonucleotide for NF-
kB or AP-1 (Promega, Madison, WI, USA).
Western Blot Analysis
Whole-cell extracts were obtained by lysing cells in ice-cold lysis
buffer (50 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 1 mM
EDTA, 1 mM phenylmethyl sulfonylfluoride) supplemented with
the protease inhibitor cocktail (BD Biosciences, San Diego, CA,
USA). In certain experiments, the nuclear extracts were prepared
using NE-PER reagent. An aliquot of protein extracts were used to
determine protein concentration by the Bradford method. Fifty mg
of whole-cell extracts or thirty mg of nuclear extract protein per
lane was separated by SDS-polyacrylamide gels and followed by
transferring to a polyvinylidene difluoride membrane (Millipore,
Bedford, MA, USA). The membrane was blocked with 5% skim
milk, and then incubated with the corresponding antibody.
Antibodies for IkBa, phosphor (Ser32)-specific IkBa, p65,
phosphor (Ser536)-specific p65, PARP, caspase-3, caspase-8, and
cIAP1 were purchased from Cell Signaling Technology (Beverly,
MA, USA). Antibodies for COX-2, ICAM-1, MMP-9, VEGF,
cyclinD1, Bcl2, FLIP, IKKa, and IKKb were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody for
TRAF2 was from R&D system (Minneapolis, MN, USA).
Antibody for a-tubulin was from Sigma (St. Louis, MO, USA).
After binding of an appropriate secondary antibody coupled to
horseradish peroxidase, proteins were visualized by enhanced
chemiluminescence according to the manufacturer’s instructions
(Amersham Pharmacia Biotec, Buckinghamshire, UK).
Kinase Assays
Human HEK293 cells grown in 100mm plates were transfected
with expression vectors for IKKa or IKKb and incubated for
24 h, and stimulated with TNF-a (20 ng/ml) for 15 min, and then
washed three times with ice-cold PBS containing 1 mM Na3VO4
and 5 mM EDTA. Cell lysates prepared in lysis buffer (20 mM
Tris-HCl, 0.5 M NaCl, 0.25% Triton X-100, 1 mM EDTA,
1 mM EGTA, 10 mM b-glycerophosphate, 10 mM NaF, 10 mM
4-nitrophenylphosphate, 300 mM Na3VO4, 1 mM benzamidine,
2 mM PMSF, 10 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml
pepstatin, and 1 mM DTT) were incubated with IKKa or IKKb
antibody on ice for 2 h. Protein A- or protein G-conjugated
agarose beads were then added and incubated for additional 2 h at
4uC. Kinase assays were performed by incubating the immune
complexes in kinase reaction buffer (20 mM HEPES, pH 7.7,
2 mM MgCl2, 10 mM ATP, 10 mM b-glycerophosphate, 10 mM
NaF, 300 mM Na3VO4, 1 mM benzamidine, 2 mM PMSF,
10 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, and
1 mM DTT) with 5 mCi of [c-
32P] ATP and bacterially expressed
GST-IkBa in a reaction volume of 20 ml for 30 min at 30uC.
Samples were analyzed by 12.5% SDS-PAGE, autoradiography,
and Western blot.
Real-Time PCR
Real-time PCR was performed as previously described [43]. In
brief, RNA was isolated from cells using RNeasy Mini kits
according to the manufacturer’s instructions (Qiagen, CA, USA).
Complementary DNA was synthesized from 1 mg of total RNA in
a2 0ml reverse transcription reaction mixture according to the
manufacturer’s protocol (TaKaRa Bio, Kyoto, Japan). The
following primer pairs were used for real-time PCR amplification:
human interleukin-6 (IL-6), 59-GAACTCCTTCTCCA-
CAAGCGCCTT -39 and 59-CAAAAGACCAGTGAT-
GATTTTCACCAGG-39; human interleukin-8 (IL-8), 59-
TCTGCAGCTCTGTGTGAAGG-39 and 59-ACTTCTCCA-
CAACCCTCTG-39; human interleukin-1 beta (IL-1b), 59-
ATGGCAGAAGTACCTAAGCTCGC-39 and 59-ACA-
CAAATTGCATGGTGAAGTCAGTT-39. GAPDH, 59-AC-
CAGGTGGTCTCCTCT-39 and 59-TGCTGTAGC-
CAAATTCGTTG-39. GAPDH was used as the housekeeping
gene control. The quantitative real-time PCR was carried out
using power SYBR green (BIO-RAD, CA, USA). Reactions were
performed in triplicate according to the manufacturer’s protocol.
In vitro Invasion Assays
The ability of cells to invade through Matrigel-coated filters was
determined using a modified 24-well Boyden chamber (Corning
Costar, Cambridge, MA, USA; 8 mm pore size). MDA-MB231
cells were seeded at a density of 5610
4 cells in 100 ml DMEM
containing 10% FBS in the upper compartment of transwell. To
determine the effect of cryptopleurine, various concentrations of
cryptopleurine were added to the lower or upper compartment of
transwell. After incubation for 24 h at 37uCi n5 %C O 2, the cells
that not penetrated the filter were completely wiped out with
a cotton swabs, and the cells that had migrated to the lower surface
of the filter were fixed, stained, and counted in 5 randomly
selected microscopic fields (1006) per filter.
Statistical Analysis
All values are expressed as mean 6 SD. A comparison of the
results was performed with one-way ANOVA and Tukey’s
multiple comparison tests (Graphpad Software, Inc, San Diego,
Inhibition of NF-kB by Cryptopleurine
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e40355CA, USA). Statistically significant differences between groups were
defined as p-values less than 0.05.
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